Privacy policy

Incyte Corporation ("Incyte") is committed to maintaining the privacy and security of your personally identifiable information collected through this Web site. This Privacy Policy sets forth Incyte's information collection and dissemination practices in connection with the Web site and applies solely to the information collected through the Web site. This Privacy Policy does not address personally identifiable information that you provide to us in other contexts. By using the Web site, you signify your acceptance of this Privacy Policy.

Personally identifiable information

With respect to the Web site, Incyte will only collect, store or use personally identifiable information (that is, any information by which you can be identified, such as name, address, email address, and telephone number, which we refer to as "Your Information"), when it is voluntarily submitted to us. You have the option not to provide any of Your Information to us. If you do provide Your Information to us, Your Information may be used to fulfill your request for information, to provide you with other information or services, to market future products and services which we think may be of interest to you, to communicate with you for other purposes, to respond to requests you may make of us, and from time to time, we may refer to Your Information to better understand your needs and how we can improve the Web site's services and we may use Your Information within the company for performing marketing studies or other analyses. We will not sell Your Information to any other company or organization. We may share Your Information with other companies or organizations that work with, or on behalf of, Incyte to provide products and services, but subject to limitations on their use or disclosure.

If you choose not to provide the information we may request, you can still visit most of the Web site, but you may be unable to access certain options and services. In general, you can visit the Web site without telling us who you are or revealing any personal information about yourself. We may track the total number of visitors to our site, the number of visitors to each page of our site, and the domain names of our visitors' Internet service providers and analyze this data for trends and statistics, but the individual user remains anonymous. From time to time we may share such aggregated data with third parties assisting us in market research.

You may update Your Information and opt out of receiving certain communications or have us stop contacting you by accessing your registration or profile. You may also opt out of receiving emails and other communications from us by using the features or other communication means contained in emails sent to you. Such requests will be subject to any applicable legal and ethical reporting or document filing or retention obligations.

Use of cookies

We may use the data we obtain through the use of cookies (small data files that a Web site transfers to your browser to store on your computer when you access a Web site) to customize your site experience by anticipating the information and services that may be of interest to you. We may also analyze the information collected with cookie technology to help us improve the functioning of the Web site by monitoring traffic in popular areas and to modify the services and information we provide to meet customer demand. We may link the data available to us through the use of cookies to the personally identifiable information and health-related information that you may choose to provide elsewhere on the Web site. We use the information we collect through the use of cookies for our business purposes, including operation of the Web site. To disable or limit the use of cookies, please refer to the options provided by your browser. If you do so, however, some portions of the Web site may not work properly.

Release in limited circumstances

In certain limited circumstances, Incyte may be required to release Your Information in response to a court order, subpoena, search warrant, law, or regulation. We also reserve the right to cooperate with law enforcement authorities in investigating and prosecuting users who violate our rules or engage in behavior that is illegal or harmful to other Web sites.

Privacy of children

We are committed to protecting the privacy of children. The site is not intended, or designed, to attract children under the age of eighteen.

Security measures

The Web site has security measures in place, including the use of industry-standard secure socket layer encryption (SSL), to protect the confidentiality of any of Your Information that you volunteer. However, to take advantage of this, your browser must support encryption protection. Regardless of the precautions taken by you or by us, perfect security does not exist on the Internet. We cannot ensure or warrant the security of any information you transmit to us, and you transmit such information at your own risk.

Links to other sites

As a convenience to our visitors, the Web site currently contains links to a number of sites that we believe may offer useful information. This Privacy Policy does not apply to those sites. We suggest contacting those sites directly for information on their privacy policies.

Additional information

The Web site is intended for use by United States residents only. Any personally identifiable information submitted at the Web site goes to Incyte in the United States and by submitting personally identifiable information to the Web site, you waive any rights you may have under any law of any other country or region.

Contact

If you have any comments or questions regarding our Privacy Policy, please contact us at support@incyte.com.

We may update this Privacy Policy from time to time. When we do update it, for your convenience, we will make the updated policy available on this page. This Privacy Policy was last updated November 2011.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.

IMPORTANT SAFETY INFORMATION

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non‐melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • The three most frequent non‐hematologic adverse reactions (incidence >10%) were bruising, dizziness and headache
  • A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breast‐feed

Please see Full Prescribing Information for Jakafi.

 
IMPORTANT SAFETY INFORMATION
 
INDICATIONS AND USAGE
Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
IMPORTANT SAFETY INFORMATION
  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non‐melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • The three most frequent non‐hematologic adverse reactions (incidence >10%) were bruising, dizziness and headache
  • A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breast‐feed

Please see Full Prescribing Information for Jakafi.